Rationale for LDH-targeted cancer immunotherapy - Université Paris Cité Accéder directement au contenu
Article Dans Une Revue European Journal of Cancer Année : 2022

Rationale for LDH-targeted cancer immunotherapy

Résumé

Immunotherapies have significantly improved the survival of patients in many cancers over the last decade. However, primary and secondary resistances are encountered in most patients. Unravelling resistance mechanisms to cancer immunotherapies is an area of active investigation. Elevated levels of circulating enzyme lactate dehydrogenase (LDH) have been historically considered in oncology as a marker of bad prognosis, usually attributed to elevated tumour burden and cancer metabolism. Recent evidence suggests that elevated LDH levels could be independent from tumour burden and contain a negative predictive value, which could help in guiding treatment strategies in immuno-oncology. In this review, we decipher the rationale supporting the potential of LDH-targeted therapeutic strategies to tackle the direct immunosuppressive effects of LDH on a wide range of immune cells, and enhance the survival of patients treated with cancer immunotherapies.
Fichier principal
Vignette du fichier
cancer_immunotherapy.pdf (1.06 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
Licence

Dates et versions

hal-04094524 , version 1 (11-05-2023)

Licence

Identifiants

Citer

Tina B.S. Miholjcic, Heloise Halse, Mélodie Bonvalet, Amélie Bigorgne, Mathieu Rouanne, et al.. Rationale for LDH-targeted cancer immunotherapy. European Journal of Cancer, 2022, 181, pp.166-178. ⟨10.1016/j.ejca.2022.11.032⟩. ⟨hal-04094524⟩
10 Consultations
3 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More